Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Accumulated Expenses (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Accumulated Expenses for 16 consecutive years, with $96.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 18.57% to $96.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.9 million through Dec 2025, down 18.57% year-over-year, with the annual reading at $96.9 million for FY2025, 18.57% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $96.9 million at Myriad Genetics, down from $108.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $164.3 million in Q2 2023, with the low at $83.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $113.0 million, with a median of $104.4 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses soared 149.54% in 2021, then tumbled 47.73% in 2022.
  • Over 5 years, Accumulated Expenses stood at $161.7 million in 2021, then crashed by 41.68% to $94.3 million in 2022, then rose by 20.78% to $113.9 million in 2023, then rose by 4.48% to $119.0 million in 2024, then fell by 18.57% to $96.9 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $96.9 million, $108.3 million, and $100.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.